Design and synthesis of novel benzimidazole derivatives as phosphodiesterase 10A inhibitors with reduced CYP1A2 inhibition.
Hamaguchi, W., Masuda, N., Isomura, M., Miyamoto, S., Kikuchi, S., Amano, Y., Honbou, K., Mihara, T., Watanabe, T.(2013) Bioorg Med Chem 21: 7612-7623
- PubMed: 24238902 
- DOI: https://doi.org/10.1016/j.bmc.2013.10.035
- Primary Citation of Related Structures:  
3WI2 - PubMed Abstract: 
A novel class of phosphodiesterase 10A (PDE10A) inhibitors with reduced CYP1A2 inhibition were designed and synthesized starting from 2-{[(1-phenyl-1H-benzimidazol-6-yl)oxy]methyl}quinoline (1). Introduction of an isopropyl group at the 2-position and a methoxy group at the 5-position of the benzimidazole ring of lead compound 1 resulted in the identification of 2-{[(2-isopropyl-5-methoxy-1-phenyl-1H-benzimidazol-6-yl)oxy]methyl}quinoline (25b), which exhibited potent PDE10A inhibitory activity with reduced CYP1A2 inhibitory activity compared to compound 1.
Organizational Affiliation: 
Drug Discovery Research, Astellas Pharma Inc., 21, Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan. Electronic address: wataru.hamaguchi@astellas.com.